Publications by authors named "E Deig"
Background: People with HIV have a substantially higher risk of anal cancer than the general population. We aimed to identify risk factors associated with the development of anal cancer among people with HIV to implement more effective and targeted screening strategies.
Methods: We conducted a multicentre retrospective cohort study in 16 hospitals across Catalonia and the Balearic Islands, Spain, between Jan 1, 1998, and Dec 31, 2022.
Article Synopsis
- COVID-19 has a greater impact on migrants and ethnic minorities, including people with HIV, highlighting the need for detailed studies on their risks and outcomes.
- A study in Catalonia analyzed data from over 10,000 people with HIV, comparing COVID-19 testing, vaccination rates, and clinical outcomes between migrants and Spanish natives.
- Results showed migrants had lower testing and vaccination rates, faced higher hospitalization and ICU admission rates, but had similar COVID-19 diagnosis rates and mortality compared to non-migrants, indicating the necessity for targeted health policies.
Background: Reports on the impact of some antiretrovirals against SARS-CoV-2 infection and disease severity are conflicting.
Objectives: We evaluated the effect of tenofovir as either tenofovir alafenamide/emtricitabine (TAF/FTC) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) against SARS-CoV-2 infection and associated clinical outcomes among people living with HIV (PLWH).
Methods: We conducted a propensity score-matched analysis in the prospective PISCIS cohort of PLWH (n = 14 978) in Catalonia, Spain.
Introduction: Standard therapy for HIV treatment has consisted of two nucleoside analogue reverse transcriptase inhibitors (NRTI) paired with a third agent. Use of two-drug regimens (2DR) has been considered for selected patients in part to avoid toxicities associated with the use of NRTIs. This study aimed to compare the real-world outcomes of integrase inhibitor (INSTI)-based three-drug regimens (3DR) versus 2DR of dolutegravir (DTG) + rilpivirine (RPV) or DTG + lamivudine (3TC).
View Article and Find Full Text PDFEvidence from clinical practice on the effects of switching from emtricitabine/tenofovir disoproxil fumarate (F/TDF) to emtricitabine/tenofovir alafenamide (F/TAF)-based triple-therapy (TT) regimens on renal parameters is limited. This retrospective analysis evaluated the effects on renal function of switching from F/TDF to F/TAF-based TT regimens with no change in third agent among people living with HIV (PLWH). Data were from a multicenter Spanish PLWH cohort.
View Article and Find Full Text PDF